News

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT. The ...
Madrigal Pharmaceuticals Reports Strong Growth Amid Challenges
Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...
MyChesCo on MSN4d
Madrigal Reports $212.8M in Q2 Rezdiffra Sales, Expands Global Pipeline and Secures $500M Financing
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported strong second-quarter results, led by surging ...
BioPharma Dive4d
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share
The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...
Madrigal signals blockbuster Rezdiffra trajectory as new patent extends exclusivity to 2045
Learn insights from Madrigal Pharmaceuticals' Q2 2025 earnings: Rezdiffra's growth, new patent till 2045, global expansion, and pipeline advances.
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat
Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...